目的 分析曲妥珠单抗与帕妥珠单抗双靶向联合化疗药物(紫杉类+卡铂)在人表皮生长因子受体2(HER-2)阳性乳腺癌新辅助治疗中的效果以及影响因素.方法 收集2020年6月1日至2022年3月31日在首都医科大学附属北京妇产医院乳腺科诊断为HER-2阳性的Ⅰ～Ⅲ期乳腺癌的41例女性患者的临床资料进行回顾性分析.观察临床疗效,评估新辅助治疗后手术切除标本的病理学完全缓解(pCR)状态并通过残余肿瘤负荷分级评估病理疗效,评价用药安全性;分析影响新辅助治疗后pCR的相关因素.结果 41例患者临床总缓解率为90.2％(37/41),病理有效率为78.0％(32/41).未出现严重不良事件.单因素分析结果显示淋巴结转移、组织学分级、脉管癌栓、孕激素受体、激素受体水平是影响pCR的相关因素,差异均有统计学意义(均P<0.05).多因素分析结果显示,激素受体阳性(比值比=5.625)、高组织学分级(比值比=4.278)、淋巴结转移(比值比=7.333)及脉管癌栓(比值比=6.000)是影响HER-2阳性乳腺癌患者新辅助治疗后pCR的独立危险因素(均P<0.05).结论 曲妥珠单抗与帕妥珠单抗双靶向联合化疗药物新辅助治疗HER-2阳性乳腺癌患者效果显著,激素受体阳性、高组织学分级、淋巴结转移与脉管癌栓是影响pCR的独立危险因素.

Objective:To study the expression of 5-fold transmembrane protein (CD133) and POU3 homobox gene 3-related long non-coding RNA (PANTR1) in breast cancer and their relationship with cell proliferation and invasion ability in vitro. Methods:A total of 50 breast cancer patients admitted to the Department of Breast Cancer, Beijing Obstetrics and Gynecology Hospital, Capital Medical University from February 2019 to February 2021 were enrolled in this study. The expression of CD133 and PANTR1 in breast cancer tissues and adjacent normal tissues was detected by reverse transcription polymerase chain reaction (PCR). In addition, McF-7 cells were divided into control group, CD133 overexpression group, PANTR1 overexpression group, CD133 inhibition group and PANTR1 inhibition group. The CD133 overexpression group was given Lipofectamine 2000 and CD133 sequence, and the PANTR1 overexpression group was given Lipofectamine 2000 and PANTR1 sequence. Lipofectamine 2000 and si-cd133 were given in CD133 inhibition group, and si-pantr1 inhibition group were given Lipofectamine 2000 and si-pantr1. The differences in proliferation and invasion ability, Pum1 and E2F3 protein expression levels in each group were analyzed. The SPSS 22.0 software was used to carry out t test. Results:The relative expression levels of CD133 and PANTR1 mRNA in breast cancer tissues were higher than those in adjacent normal tissues (0.021±0.001 vs. 0.006±0.001, 0.016±0.002 vs. 0.005±0.001, t=75.000, 74.785, P<0.01). After transfection for 24, 48 and 72 h, the proliferation rate of CD133 overexpression group was higher than that of control group (3.05±0.26, 5.40±0.47 and 10.74±1.27 vs. 2.17±0.25, 4.38±0.42, 6.97±0.84, t=4.226, 2.783, 4.298, all P<0.05), and the number of invasive cells at 24 h after transfection was greater than that of the control group (75.29±7.19 vs. 54.01±6.27, t=3.865, P<0.05). After transfection for 24, 48 and 72 h, the proliferation rate of PANTR1 overexpression group was higher than that of the control group (3.11±0.28, 5.45±0.51 and 10.05±1.24 vs. 2.17±0.25, 4.38±0.42, 6.97±0.84, t=4.372, 3.003, 3.570, all P<0.05), and the number of invasive cells at 24 h after transfection was greater than that of the control group (76.03±7.26 vs. 54.01±6.27, t=3.977, P<0.01). The expression levels of Pum1 and E2F3 protein in CD133 overexpression group were higher than those in control group (4.52±0.75, 3.38±0.56 vs. 1.00±0.04, 1.00±0.03, t=8.118, 7.351, P<0.05). The expression levels of Pum1 and E2F3 protein in PANTR1 overexpression group were higher than those in control group (4.55±0.76, 3.41±0.59 vs. 1.00±0.04, 1.00±0.03, t=8.079, 7.066, P<0.01). The expression levels of Pum1 and E2F3 protein in CD133 inhibition group were lower than those in control group (0.45±0.02, 0.37±0.03 vs. 1.00±0.04, 1.00±0.03, t=21.301, 25.720, P<0.01). Pum1 and E2F3 protein expression levels in panTR1-inhibition group were lower than those in control group (0.47±0.03, 0.38±0.02 vs. 1.00±0.04, 1.00±0.03, t=18.360, 29.784, P<0.01). Conclusion:Both CD133 and PANTR1 are significantly overexpressed in breast cancer, and can enhance cell proliferation and invasion ability in vitro, which deserves clinical attention.

目的 探讨microRNA-301a(miR-301a)对三阴性乳腺癌(TNBC)细胞的侵袭、增殖的调控作用及潜在的作用机制.方法 应用real-time PCR检测miR-301a在MDA-MB-231细胞与MCF-10A细胞中的表达;转染MDA-MB-231,按转染质粒分为Mimics miR-301a组、Mimics NC组、Inhibitor miR-301a组、Inhibitor NC组,通过Transwell小室实验、M T T实验检测miR-301a对MDA-MB-231细胞侵袭及增殖能力的影响;应用生物信息学软件预测miR-301a的下游靶点,并应用荧光素酶报告实验以及Western blot分析miR-301a对靶点的调节作用.结果 miR-301a在MDA-MB-231细胞中的表达明显高于正常乳腺细胞(P<0.05);Transwell小室实验提示过表达miR-301a能够增强MDA-MB-231细胞的侵袭能力(P<0..05);MTT实验提示过表达miR-301a能够增强MDA-MB-231细胞的增殖能力(P<0.05);荧光素酶报告实验以及western blot实验证实miR-301a与MEOX2的靶向关系,Mimics miR-301a组MEOX2蛋白表达量明显低于Mimics NC组和空白组(P<0.05),Inhibitor miR-301a组MEOX2蛋白表达量明显高于Inhibitor NC组和空白组(P<0.05).结论 miR-301a在T NBC中高表达,并可通过靶向作用于M EOX2促进T NBC细胞的侵袭、增殖,从而作为T NBC的促癌基因发挥作用.

目的 探讨三阴性乳腺癌(triple negative breast cancer,TNBC)患者肿瘤组织程序性死亡分子-1(PD-1)/程序性死亡配体-1(PDL-1)的表达水平,及其与肿瘤临床特征和T淋巴细胞免疫功能的相关性.方法 选择2018年6月—2020年2月入我院经病理确诊的TNBC患者76例(TNBC组),非TNBC患者124例(非TNBC组),乳腺良性肿瘤50例(良性组).分别检测3组肿瘤组织中PD-1和PDL-1表达,T淋巴细胞亚群CD4+、CD8+和调节性T细胞(Treg)百分比;探讨3组PD-1和PDL-1定量表达与CD4+、CD8+和Treg百分比的相关性;分析TNBC组PD-1和PDL-1表达与肿瘤临床特征的关系.结果 TNBC组PD-1和PDL-1阳性表达率和定量表达水平均明显高于非TNBC组和良性组,非TNBC组亦明显高于良性组,差异有统计学意义(P<0.05).TNBC组CD4+、CD8+和Treg百分比均明显低于非TNBC组和良性组,非TNBC组亦明显低于良性组,差异有统计学意义(P<0.05).相关分析发现,PD-1和PDL-1定量表达水平与CD4+、CD8+和Treg百分比呈负相关性(P<0.01).TNBC组PD-1和PDL-1阳性表达率在肿瘤TNM分期、组织学分级和淋巴结转移方面有显著差异(P<0.05或P<0.01).结论 TNBC患者肿瘤组织中PD-1/PDL-1异常高表达可能与T淋巴细胞免疫功能抑制和肿瘤恶性生物学行为有关.

目的:探讨绝经前乳腺癌患者化疗致闭经(CIA)的影响因素.方法:收集2016至2018年的305例行辅助化疗的绝经前乳腺癌患者,随访其化疗后月经变化情况,分析CIA发生的影响因素.结果:CIA发生率为69.51％(212/305),其中月经恢复率为44.8％(95/212).年龄与CIA发生率、月经恢复情况均显著相关(P<0.05).年轻的患者表现出更低的CIA发生率和更高的月经恢复率.但孕产次、腋窝淋巴结转移与否、雌激素受体(ER)、孕激素受(PR)、HER-2状况、病理分期等因素与CIA发生率均无显著相关性(P>0.05).行AC-T和TAC/AT化疗方案的患者CIA发生率高于行TC方案的患者(P<0.05).用他莫昔芬内分泌治疗的患者CIA发生率为72.63％,略高于未使用者,但无统计学差异(P>0.05).结论:年龄显著影响绝经前乳腺癌患者的CIA发生率,且随着年龄的增大,CIA发生几率增加,月经恢复几率减少.此外,蒽环类与紫杉类药物联合或序贯使用可导致CIA发生率较高.

目的 探讨麦默通旋切术(Mammotome,MMT)用于乳腺癌病灶切除的临床价值.方法 接受超声引导下MMT,术后病理检查确诊为乳腺癌,并接受再次开放手术病人75例,根据MMT后有无肿瘤残留分为肿瘤残留组和肿瘤无残留两组,肿瘤残留组39例,肿瘤无残留组36例.分析乳腺癌肿瘤病灶残留与临床、病理因素间的关系.结果 乳腺癌MMT后肿瘤病灶残留率为52.0％.年龄、组织学类型、Ki-67表达与乳腺癌肿瘤病灶残留相关(P<0.05);年龄是乳腺癌肿瘤病灶残留的独立危险因素,P<0.05.结论 乳腺癌经超声引导下MMT切除肿瘤病灶,肿瘤残留率偏高.不建议应用MMT治疗乳腺癌.

BACKGROUND:Breast cancer (BC) is a common cancer with high incidence in women worldwide. Although there are some studies focusing on the pathogenesis of BC, the regulatory mechanism needs to be further investigated. The function of lncRNA and miRNA has been demonstrated to participate in cell progression of BC. However, the function of SNHG12 has not been clearly elucidated.METHODS:We detected the expression of SNHG12 and miR-451a using quantitative real-time PCR (qRT-PCR). The protein expression of AKT, p-AKT, mTOR and p-mTOR were measured using western blot. The relationship between SNHG12 and miR-451a was confirmed by luciferase reporter assay. Cell proliferation was measured using MTT assay. Transwell assay was used to detect cell migration and invasion. Xenograft transplantation was used to detect the function of SNHG12 in vivo.RESULTS:In this study, we found that SNHG12 was significantly increased in BC tissues and cells. Knockdown of SNHG12 inhibited BC cell proliferation, invasion, and migration in vitro as well as suppressed tumor growth in vivo. In addition, miR-451a expression was obviously down-regulated in BC tissues and had negative correlation with SNHG12. Luciferase reporter assay determined that miR-451a was a target miRNA of SNHG12. Notably, SNHG12 knockdown decreased cell proliferation, migration, invasion, and AKT/mTOR pathway activation which could be reversed by down-regulation of miR-451a.CONCLUSION:Knockdown of SNHG12 inhibited cell proliferation, invasion, and migration by regulating miR-451a through suppression of AKT/mTOR pathway in BC.

目的 探讨1～2枚前哨淋巴结(SLN)阳性的乳腺浸润性导管癌患者非前哨淋巴(NSLN)转移与临床特征的关系.方法 收集58例接受SLN活检术,病理提示SLN转移1～2枚,并进一步接受腋窝淋巴结清扫术的乳腺浸润性导管癌患者,分析并比较不同临床特征患者的NSLN阳性率.结果 58例1～2枚SLN阳性乳腺癌患者中,30例(51.7％)患者NSLN阴性,28例(48.3％)患者NSLN阳性.SLN阳性/总SLN≥0.5的患者NSLN阳性率高于SLN阳性/总SLN﹤0.5的患者,差异有统计学意义(P﹤0.05).不同年龄、月经状态、肿瘤最大径、脉管瘤栓、雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)、Ki-67、SLN阳性数的乳腺癌患者的NSLN阳性率比较,差异均无统计学意义(P﹥0.05).结论 1～2枚SLN阳性的乳腺浸润性导管癌患者仍然存在NSLN阳性风险,SLN阳性/总SLN≥0.5时,NSLN阳性率较高.

前哨淋巴结活检术(sentinel lymph node biopsy,SLNB)主要用于腋窝淋巴结阴性的早期乳腺癌患者,前哨淋巴结阴性者可免除腋窝淋巴结清扫术.但SLNB在非早期乳腺癌患者新辅助化疗过程中的应用是否具有同样的价值,以及如何保证准确率及假阴性率,目前尚无统一共识.本文就SLNB在乳腺癌患者新辅助化疗应用中的研究进展进行综述.

目的 探讨曲妥珠单抗联合新辅助化疗治疗人表皮生长因子受体2(HER2)阳性乳腺癌的临床疗效及对患者生存质量的影响.方法 采用抽签法随机将30例HER2阳性女性乳腺癌患者分为对照组和观察组,每组15例.对照组患者术前接受新辅助化疗,观察组患者术前接受曲妥珠单抗联合新辅助化疗,比较两组患者的临床疗效、治疗前后的肿瘤相关炎性因子[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)]水平以及治疗前和治疗后8个月的生存质量.结果 观察组患者的总有效率为86.67％(13/15),高于对照组患者的53.33％(8/15),差异有统计学意义(P﹤0.05).治疗前,两组患者的血清IL-6、IL-8、TNF-α、IL-1β水平比较,差异均无统计学意义(P﹥0.05);治疗后,观察组患者的血清IL-6、IL-8、TNF-α、IL-1β水平均明显低于对照组患者,差异均有统计学意义(P﹤0.01).治疗前,两组患者的生存质量评分比较,差异无统计学意义(P﹥0.05);治疗后8个月,观察组患者的生存质量评分明显高于对照组患者,差异有统计学意义(P﹤0.01).结论 与术前单纯新辅助化疗相比,术前曲妥珠单抗联合新辅助化疗治疗HER2阳性乳腺癌可获得更好的临床疗效,且可有效改善患者的生存质量.

目的 探讨前哨淋巴结(sentinel lymph node,SLN)阳性乳腺癌患者非前哨淋巴结(non-sentinel lymph node,NSLN)转移的影响因素. 方法 回顾性分析2015年1月～2018年6月我科行SLNB提示SLN阳性并行腋窝淋巴结清扫(axillary lymph node dissection,ALND)的女性乳腺癌患者69例,其中NSLN阴性33例(47.8％),阳性36例(52.2％).采用单因素和多因素Logistic分析NSLN转移的影响因素. 结果 单因素分析结果显示:乳腺癌患者NSLN转移与SLN总数(P=0.021)和SLN+/总SLN(P=0.003)有关,与患者年龄(P=0.805)、月经状态(P=0.627)、肿块大小(P=0.110)、是否有脉管癌栓(P=0.088)、SLN转移数目(P=0.102)以及ER(P=0.847)、PR(P=0.453)、HER2(P=0.071)、Ki67(P=0.623)不相关(P＞0.05);多因素Logistic回归分析显示,SLN阳性比例(SLN+/总SLN)为乳腺癌NSLN转移的独立危险因素(P=0.005). 结论 SLN阳性的乳腺浸润性导管癌患者存在较高的NSLN阳性风险,SLN阳性比例为影响NSLN转移的独立危险因素.SLN+/SLN比值≥0.5时,NSLN转移率显著增高,在免除ALND时应慎重考虑.

目的 分析非哺乳期乳腺炎的诊治方法.方法 非哺乳期乳腺炎病人48例,对其临床资料进行回顾性分析.结果 48例病人中,36例(75％)表现为乳房单发质硬肿物,10例(20.8％)表现为单侧肿块合并脓肿形成,2例(4.2％)病人表现为双侧乳房炎症.36例单发肿物病人中,29例行门诊口服西黄胶囊,23例有效,总有效率79.5％,其余7例手术治疗,除1例术后感染残腔脓肿形成以外,恢复均顺利;10例单侧肿块脓肿形成病人中,7例行脓肿切开引流术,3例行脓肿穿刺抽吸配合庆大霉素脓腔注入抗炎治疗,脓肿渐消除缓解,9例脓肿病例行口服西黄胶囊保守治疗,6例有效,有效率66.7％;2例双侧乳腺炎症病人行双乳区段切除术或双乳全切术.术后恢复良好.总之,48例病人中共15例(31.3％)接受手术切除治疗,西黄胶囊总有效率76.3％(29/38).结论 手术是非哺乳期乳腺炎主要的根治性治疗方式,西黄胶囊作为重要的保守治疗手段值得重视.

目的 探讨原发性浸润性乳腺癌患者发生脉管浸润的相关危险因素.方法 采用多因素Logistic回归模型分析365例原发性浸润性乳腺癌患者发生脉管浸润的独立危险因素.结果 365例原发性浸润性乳腺癌患者中,91例患者发生了脉管浸润.单因素分析结果显示,不同腋窝淋巴结转移数量、TNM分期、组织学分级、Ki-67表达水平和分子分型原发性浸润性乳腺癌患者的脉管浸润发生率比较,差异均有统计学意义(P﹤0.05).多因素分析结果显示,腋窝淋巴结转移数量﹥3个、TNM分期为Ⅲ期、分子分型为Luminal B型、分子分型为HER2阳性型、分子分型为三阴性均是原发性浸润性乳腺癌患者发生脉管浸润的独立危险因素(P﹤0.05).结论 腋窝淋巴结转移数量﹥3个、TNM分期为Ⅲ期、分子分型为Luminal B型、分子分型为HER2阳性型、分子分型为三阴性的原发性浸润性乳腺癌患者发生脉管浸润的风险较高,因此要对该部分患者重点关注,早发现、早治疗,降低脉管浸润的发生率.

原发性乳腺神经内分泌癌是乳腺癌当中的一种罕见的特殊类型,从其第一次被描述至今已有50余年历史,因业内对其认识的不断改变和加深,诊断标准也多次更新,直到2003年世界卫生组织(WHO)才首次明确了定义和诊断标准.该病发病率低,病例数少,目前对其疾病起源尚无定论,亦无针对性的临床治疗指南或规范,大样本,前瞻性的临床研究也有所缺乏,治疗往往参考非特殊型乳腺癌的方案.本文通过查阅相关文献对原发性乳腺神经内分泌癌目前的研究现状进行综述,以期对未来临床研究方向提供建议和参考,为今后的临床实践提供更多借鉴和帮助.

Objective To study the clinical value of minimally invasive surgery Mammotome in diagnosing and treating early breast cancer.Methods The clinical data from 41 cases of breast cancer underwent Mammotome from January 2015 to June 2016,were retrospectively analyzed.Results Patients aged 35~50 years old accounted for the highest proportion in patients with breast cancer underwent mini-mally invasive surgery,and patients aged older than 50 years old of age was on the contrary.The incidence of breast cancer in the upper outer quadrant was significantly higher than the other quadrants.The diame-ter of 83% lesions were no more than 20 mm and 85% of all cases had no axilla lymph node metastasis, which suggested that MMT biopsy had advantage of diagnosing early breast cancer.BI-RADS reported as 4a,but MMT biopsy of malignancy accounted for 71%.All cases had no local recurrence and metastasis in 3-months,6-months and 12-months follow-up.Conclusion Mammotome-biopsy not only removes tumors with minimal invasion,but also is good for early diagnosis and therapy of breast cancer.

三阴性乳腺癌(TNBC)是一种特殊类型的乳腺癌,占所有乳腺癌的15％～20％,其雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)表达均为阴性,具有独特的生物学特性和临床特征,肿瘤异质性较高,临床上具有复发率高、转移早和预后差等特点.化疗是TNBC主要的辅助治疗手段,但总体预后仍较差.随着TNBC分子生物学特征研究的不断深入,相关靶向药物研究及临床试验陆续开展,目前取得了一些积极的临床试验结果.中医药治疗作为传统的医疗手段,对于晚期乳腺癌也发挥着重要的支持扶正作用.本文就TN-BC的治疗进展作一综述.

目的 分析乳腺浸润性导管癌(invasive ductal carcinoma of breast)的分子分型与其临床病理特征的关系.方法 选择首都医科大学附属北京妇产医院2015年1月至2016年10月诊治的女性乳腺浸润性导管癌患者198例,根据免疫组化检测结果将乳腺癌分为4个分子亚型,即Luminal A型、Luminal B(HER-2阴性/HER-2阳性)型、HER-2过表达型和三阴性乳腺癌,分析不同分子亚型在发病部位、年龄、肿瘤大小、腋窝淋巴结转移、病理分期、组织学分级、脉管癌栓和手术方式方面的差异,以及Ki-67表达与雌激素受体(estrogen reseptor,ER)、孕激素受体(proges-terove,receptor,PR)表达的关系.结果 乳腺浸润性导管癌的病灶位置、发病年龄、手术方式在分子各亚型组间差异均无统计学意义(P＞0.05);肿瘤大小、淋巴结转移、pTNM分期、组织学分级及脉管癌栓情况在各亚型组间差异均有统计学意义(P＜0.05).Ki-67的表达水平与ER、PR的表达存在相关性(P＜ 0.05).结论 乳腺浸润性导管癌的分子分型与患者生存及转移模式密切相关,对指导临床个体化治疗具有重要意义.

Objective To investigate the effect of HMGB2 silencing on proliferation, apoptosis, invasion and migration of breast cancer cell line MDA?MB?231. Methods The lentiviral vector was constructed by cloning the oligonucleotides targeting HMGB2 into pLKO.1 puro vector. MDA?MB?231 cells were divided into control group, empty transfection group and HMGB2 interference group. The empty transfection group was transfected with random sequence shRNA and HMGB2 interference group was transfected with lentivi?ral vector targeting HMGB2 shRNA. The control group was treated with routine culture without any transfection. Western blotting was used to detect the level of HMGB2 protein after transfection for 48 h in each group to evaluate the efficiency of transfection. MTT meth?od was used to calculate the survival rate of each group. Flow cytometry was used to detect the apoptosis rate after transfection for 48 h. The Transwell method was used to detect the invasion and metastasis of 48 h after transfection. Results The level of HMGB2 protein in the HMGB2 interference group was lower than those in control group and empty transfection group, and the difference was statistical?ly significant ( P<005) . Compared with control group and empty transfection group, the survival rate of HMGB2 interference group was decreased, and there was a decreasing trend with the increase of transfection time ( P<005) . The early, late and total apoptosis rates of HMGB2 interference group were higher than those in the other two groups, and the number of invasive cells and the number of migrating cells were lower than the other two groups ( P<005) . Conclusion Silencing HMGB2 expression via shRNA in MDA?MB?231 cells has a significant effect, can inhibit cell proliferation, invasion, migration and induce cell apoptosis, to provide a reference for breast cancer targeted therapy.

乳腺导管内乳头状瘤是一种多发于乳腺导管上皮细胞的良性肿瘤[1].发病症状主要体现为乳头呈现硬块,且乳头间歇性溢液或溢血,好发于产后、40～50岁绝经前的妇女,病因目前尚不明确[2].主要分为两大类型,分别是中央型和周围型,中央型常发于乳晕区输乳管壶腹部内的大导管,主要特征为乳头溢液.周围型则常发于乳腺周围末梢、小导管中,通常情况下为多发[3].该病症有一定的癌变概率,一般通过外科手术进行治疗,可采用传统开放性手术和超声引导下真空辅助微创旋切手术来进行治疗[4].本研究分析超声引导下真空辅助微创旋切乳腺导管内乳头状瘤的疗效,现将结果报告如下.

Objective:To evaluate the diagnosis and curative value of double localization method that mammary ductoscopy combined with methylene blue staining for tumor-like lesion in mammary duct of patients with pathological nipple discharge.Methods: The documents of 80 patients with tumor-like lesion in mammary duct who underwent the detection of double localization that mammary ductoscopy combined with methylene blue staining before operation were researched by using retrospective analysis, and then the diagnostic results were compared with pathological results so as to evaluate the curative effect of surgery.Results: The coincidence rate of the diagnosis of intraductal papilloma between mammary ductoscopy and post-operative pathological results was 83.3%, and the coincidence rate of breast carcinoma was 80%. The differences of distributions of benign lesion and malignant lesion in mammary duct of I-III grade were significant (x2=30.026,P<0.05). Besides, all of operations were accuracy in localization, and the surface of wound were small, and the recurrent cases never been found since the start of follow-up.Conclusion: The double localization method that mammary ductoscopy combined with methylene blue staining has important value in the diagnosis and operative treatment.